Hypertension and hypercholesterolaemia as risk factors for Alzheimer's disease: Potential for pharmacological intervention

CNS Drugs

Volumn 16, Issue 7, 2002, Pages 435-444

  Kivipelto, Miia ^a   Laakso, Mikko P ^a   Tuomilehto, Jaakko ^b   Nissinen, Aulikki ^b   Soininen, Hilkka ^a,c  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 [1 (4 CHLOROCINNAMYL) 4 PIPERAZINYL]ETHYL]BENZOIC ACID; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRENDIPINE; SIMVASTATIN; STATIN;

ALZHEIMER DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CLINICAL TRIAL; COGNITION; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG INDICATION; ENVIRONMENTAL FACTOR; GENETIC RISK; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INCIDENCE; NONHUMAN; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE;

EID: 0036300343     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200216070-00001     Document Type: Review

References (55)

1. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset
2. Vascular risk factors for Alzheimer's disease: An epidemiologic perspective
3. Are cognitive function and blood pressure related?
4. 15-year longitudinal study of blood pressure and dementia
5. Serum total cholesterol, apolipoprotein E ε4 allele, and Alzheimer's disease
6. Midlife blood pressure and dementia: The Honolulu-Asia aging study
7. Midlife vascular risk factors and Alzheimer's disease in later life: Longitudinal, population-based study
8. Association of incident Alzheimer's disease and blood pressure measured from 13 years before to 2 years after diagnosis in a large community study
9. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham Heart Study
10. Association between features of the insulin resistance syndrome and Alzheimer's diseases independently of apolipoprotein e4 phenotype: Cross sectional population based study
11. ApoE genotype, plasma lipids, lipoproteins, and Alzheimer's disease in community elderly
12. The effect of apoE on dementia is not through atherosclerois: The Rotterdam Study
13. Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: A case-control study
14. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the systolic hypertension in the elderly program (SHEP)
15. Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's treatment trial of hypertension in older adults
16. Prevention of dementia in randomised double-blind placebo-controlled systolic hypertension in Europe (Syst-Eur) trial
17. Occurrence and progression of dementia in a community population aged 75 years and older: Relationship of antihypertensive medication use
18. Antihypertensive drugs and incidence of dementia: The Rotterdam Study
19. Decreased prevalence of Alzheimer disease associated with 3-hydroxy -3-methyglutaryl coenzyme A reductase inhibitors
20. Statin-Alzheimer disease association not yet proven [letter]
21. Statins and the risk of dementia
22. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people
23. Hypertension awareness, treatment and control in the community: Is the "rule of halves" still valid?
24. Trends in blood pressure levels and control of hypertension in Finland from 1982 to 1997
25. Actual blood pressure control: Are we doing things right?
26. Neurologic consequences of hypertension and antihypertensive drug therapy
27. Neuropathology of Alzheimer's disease: What is new since A. Alzheimer?
28. Comparative effects of pravastatin and lovastatin on nighttime sleep and daytime performance
29. Effects of lovastatin on cognitive function and psychological well-being
30. Central nervous system effects of HMG CoA reductase inhibitors: Lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia
31. Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers
32. Effects of treatment with lovastatin and pravastatin on daytime cognitive performance
33. Effects of pharmacologic lipid lowering on health-related quality of life in older persons: Results from the cholesterol reduction in seniors program (CRISP) pilot study
34. The neurobiology of apolipoproteins and their receptors in the CNS and Alzheimer's disease
35. Cholesterol and Alzheimer's disease: Is there a link?
36. Vascular factors and Alzheimer disease
37. The influence of coincidental vascular pathology on symptomatology and course of Alzheimer's disease
38. Brain infarction and the clinical expression of Alzheimer's disease: The Nun Study
39. Increased incidence of neurofibrillary tangles (NFT) in non-demented individuals with hypertension
40. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: The HAAS
41. Cholesterol reduction in cardiovascular disease: Clinical benefits and possible mechanisms
42. Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo
43. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase Alzheimer's disease AM 10
44. Is there a connection between the concentration of cholesterol circulating in plasma and the rate of neuritic plaque formation in Alzheimer disease?
45. A fluid connection: Cholesterol and Aβ
46. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons
47. A cholesterol-lowering drug reduces β-amyloid pathology in a transgenic mouse model of Alzheimer's disease
48. Cholesterol Aβ Alzheimer's disease
49. The relationship between cholesterol and stroke
50. Use of statins in CNS disorders
51. Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: Evidence that simvastatin affects cholesterol metabolism in the human brain
52. Copernicus revisited: Amyloid beta in Alzheimer's disease
53. Overlap between pathology of Alzheimer's disease and vascular dementia
54. Are vascular factors involved in Alzheimer's disease? Facts and theories
55. Alzheimer's disease and vascular dementia: Some points of confluence